A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Open accessThe DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
An HIV antibody achieves potency and breadth by binding simultaneously to two conserved glycans on the viral envelope protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [508]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
EMAN2: An extensible image processing suite for electron microscopy
Tang, G., Peng, L., Baldwin, P. R., Mann, D. S., Jiang, W., Rees, I., & Ludtke, S. J. (2007) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.05.009 · Cited by 2,994
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
EMAN: Semiautomated Software for High-Resolution Single-Particle Reconstructions
Ludtke, S. J., Baldwin, P. R., & Chiu, W. (1999) · Journal of Structural Biology · doi:10.1006/jsbi.1999.4174 · Cited by 2,391
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Self-citationBroad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Self-citation
Cited by
Items 501–600 of 709
Gieselmann, L., DeLaitsch, A. T., Rohde, M., Radford, C. E., Worczinski, J., Ashurov, A., Ahmadov, E., Burger, J. A., Havenar‐Daughton, C., Deshpande, S., et al. (2026) · Nature Immunology · doi:10.1038/s41590-025-02385-3 · Cited by 10
“However, the extent to which enhanced pseudovirus neutralization by 007 IgG can be attributed to viral aggregation, intra-spike crosslinking or another mechanism such as inter-spike crosslinking 13,30 or heteroliga-tion 38 or by enhancing gp120 shedding 37 warrants further investigation.”
Antibodies Targeting the Envelope of HIV-1
Mayr, L. M., & Zolla‐Pazner, S. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0025-2014 · Cited by 10
Andrabi, R., Bala, M., Kumar, R., Wig, N., Hazarika, A., & Luthra, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043704 · Cited by 10
Human transitional and IgMlow mature naïve B cells preserve permissive B‐cell receptors
Zhang, Z., Jara, C. J., Singh, M., Xu, H., Goodnow, C. C., Jackson, K., & Reed, J. H. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12478 · Cited by 10
Sattentau, Q. J. (2011) · Nature · doi:10.1038/480324a · Cited by 10
HIV-Specific Antibody Responses in HIV-Infected Patients: From a Monoclonal to a Polyclonal View
Gallerano, D., Cabauatan, C. R., Sibanda, E., & Valenta, R. (2015) · International Archives of Allergy and Immunology · doi:10.1159/000438484 · Cited by 10
Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits
Qin, Y., Shi, H., Banerjee, S., Agrawal, A., Banasik, M., & Cho, M. W. (2014) · Retrovirology · doi:10.1186/s12977-014-0125-5 · Cited by 13
“Antibodies used for competition included VRC01 [26], CD4-IgG2 [29], 447-52D [30-35], PGT121 [36,37], PGT126 [36], and 2G12 [38-42].”
InfluentialOptimization of peptide arrays for studying antibodies to hepatitis C virus continuous epitopes
Ruwona, T. B., McBride, R., Chappel, R., Head, S. R., Ordoukhanian, P. T., Burton, D. R., & Law, M. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.11.005 · Cited by 10
Self-citationMartines, E., García, I., Marradi, M., Padró, D., & Penadés, S. (2012) · Langmuir · doi:10.1021/la303484e · Cited by 10
Johnson, J., Zhai, Y., Salimi, H., Espy, N., Eichelberger, N., DeLeon, O., O’Malley, Y., Courter, J. R., Smith, A. B., Madani, N., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00174-17 · Cited by 10
IgM Antibodies Can Access Cryptic Antigens Denied to IgG: Hypothesis on Novel Binding Mechanism
Law, E. C. Y., Leung, D. T. M., Tam, F. C. H., Cheung, K. K. T., Cheng, N. H.-Y., & Lim, P. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01820 · Cited by 11
“However, a small fraction of the antibodies, coined “broadly neutralizing antibodies,” manage to penetrate the glycan shield and reach the target through unusually long HCDR3 projections (38, 43).”
BackgroundHabte, H. H., Banerjee, S., Shi, H., Qin, Y., & Cho, M. W. (2015) · Virology · doi:10.1016/j.virol.2015.09.010 · Cited by 10
“, 2003) and determining high-resolution structures of the bnAbs (Huang et al., 2012; Julien et al., 2013b; Pejchal et al., 2011; Scharf et al., 2014; Zhou et al., 2010) as well as novel envelope antigens (e.”
BackgroundWang, D., Tang, J. Y., Tang, J., & Wang, L. (2015) · Molecules · doi:10.3390/molecules20034610 · Cited by 10
“Discovery of oligomannosyl moieties as targets of bnAbs against HIV-1 has stimulated substantial interest in carbohydrate moieties as vaccine candidates [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] .”
Tarazona, A. A. P., Laurent, E., Taubenschmid, Y., Paireder, M., Acosta, J. A. T., Göritzer, K., Steinkellner, H., & Mach, L. (2019) · Biotechnology Journal · doi:10.1002/biot.201900308 · Cited by 10
Ritchie, C. (2012) · Materials and Methods · doi:10.13070/mm.en.2.134 · Cited by 13
Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160ΔcBaL
Gaebler, C., Gruell, H., Velinzon, K., Scheid, J. F., Nussenzweig, M. C., & Klein, F. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.09.003 · Cited by 10
“…of bNAbs, including the CD4 binding site (Wu et al., 2010; Diskin et al., 2011; Scheid et al., 2011), the base of the V3 loop (Walker et al., 2009; Pejchal et al., 2011; Walker et al., 2011; Mouquet et al., 2012), the V1/V2 loops (Walker et al., 2009; Bonsignori et al., 2011; Walker et al.,…”
BackgroundA Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen
Vijayan, A., García‐Arriaza, J., Raman, S. C., Conesa, J. J., Chichón, F. J., Santiago, C. A., Sorzano, C. Ó. S., Carrascosa, J. L., & Estéban, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133595 · Cited by 11
Girard, M. P., Picot, V., Longuet, C., & Nabel, G. J. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.068 · Cited by 11
Broadly Neutralizing Antibodies and the Promise of Universal Vaccines: Where are we Now?
Hefferon, K. L. (2013) · Immunotherapy · doi:10.2217/imt.13.150 · Cited by 9
Margolin, E., Allen, J. D., Verbeek, M., Chapman, R. E., Meyers, A. E., van Diepen, M. T., Ximba, P., Motlou, T. P., Moore, P. L., Woodward, J. D., et al. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28169 · Cited by 9
Self-citationNeonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies
Hora, B., Li, H., Shen, X., Martin, M., Chen, Y., Berry, M., Evangelous, T. D., Macintyre, A. N., Arus-Altuz, A., Wang, S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112255 · Cited by 9
Self-citationAmos, J. D., Himes, J. E., Armand, L. C., Gurley, T. C., Martinez, D. R., Colvin, L., Beck, K., Overman, R. G., Liao, H., Moody, M. A., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01564-15 · Cited by 9
Opening dynamics of HIV-1 gp120 upon receptor binding is dictated by a key hydrophobic core
Da, L., & Lin, M. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp04613e · Cited by 9
Coevolution Analysis of HIV-1 Envelope Glycoprotein Complex
Rawi, R., Kunji, K. B., Haoudi, A., & Bensmail, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143245 · Cited by 9
“Despite that several crystal and cryo-electron microscopy/ tomography structures of gp120 in unliganded state exist [6–25] (as well as in complex with CD4, CD4 mimics, or various antibodies, and of gp41 in intermediate and post-fusion state), a comprehensive understanding of structural arrangements and communication w…”
BackgroundStructural N- and O-glycans revealed by high-resolution cryo-EM analysis of tubular mastigonemes
Huang, J., Tao, H., Chen, S., Cui, Y., Xu, Y., Yan, C., & Yan, N. (2026) · Science · doi:10.1126/science.aef4958 · Cited by 11
Shipley, M. M., Prasad, V. M., Doepker, L. E., Dingens, A. S., Ralph, D., Harkins, E., Dhar, A., Arenz, D., Chohan, V., Weight, H., et al. (2021) · eLife · doi:10.7554/elife.68110 · Cited by 8
Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection
Chen, J., Li, Y., & Liu, Z. (2023) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2023.101249 · Cited by 9
Trapping the HIV-1 V3 loop in a helical conformation enables broad neutralization
Glögl, M., Friedrich, N., Cerutti, G., Lemmin, T., Kwon, Y. D., Gorman, J., Maliqi, L., Mittl, P. R. E., Hesselman, M. C., Schmidt, D. G., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01062-z · Cited by 8
Yang, Z., Li, J., Liu, Q., Yuan, T., Zhang, Y., Chen, L.-Q., Lou, Q., Sun, Z., Ying, H., Xu, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126428 · Cited by 8
“Some bnAbs have been crystallized and their neutralizing epitopes identified [9–16].”
BackgroundDunkel, A. L., Shen, S., LaBranche, C. C., Montefiori, D. C., & McGettigan, J. P. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2014.0319 · Cited by 8
Gene therapy as a vaccine for HIV-1
Berkhout, B., & Sanders, R. W. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707177 · Cited by 10
“of antibodies were identified that are dependent on specific glycans on gp120, including antibodies with defined and conserved composite glycan-peptide epitopes in the V1V2 domain (PG9) and the V3 (PGT128) [23,26,31,32].”
BackgroundSelf-citationDutta, M., Liu, J., Roux, K. H., & Taylor, K. A. (2014) · Journal of Virology · doi:10.1128/jvi.01596-14 · Cited by 8
Isik, G., van Montfort, T., Boot, M., Jiménez, V. C., Kootstra, N. A., & Sanders, R. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060126 · Cited by 8
Self-citationElectroporation-Mediated Administration of Candidate DNA Vaccines Against HIV-1
Vasan, S. (2014) · Methods in molecular biology · doi:10.1007/978-1-4614-9632-8_26 · Cited by 8
Cheedarla, N., Precilla, L. K., Babu, H., Vijayan, K. K. V., Ashokkumar, M., Padmapriyadarsini, C., Kailasam, N., Sundaramurthi, J. C., Swaminathan, S., Viswanath, B., et al. (2017) · Scientific Reports · doi:10.1038/srep46557 · Cited by 8
‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
Stamatatos, L. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000817 · Cited by 9
Zhang, Z., Anang, S., Nguyen, H. T., Fritschi, C. J., Smith, A. B., & Sodroski, J. (2024) · iScience · doi:10.1016/j.isci.2024.110141 · Cited by 8
Cohen, Y. Z., Lavine, C. L., Miller, C. A., Jetta, G., Carey, B. R., & Seaman, M. S. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0135 · Cited by 8
“These include N295, N339, N386, and N392 for mAb 2G1214; N156 for mAbs PG9 and PG16 10; and N301 for mAb PGT128.”
BackgroundComparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers
Bontjer, I., Melchers, M., Tong, T., van Montfort, T., Eggink, D., Montefiori, D. C., Olson, W. C., Moore, J. P., Binley, J. Μ., Berkhout, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067484 · Cited by 8
“The recent discovery of many broadly neutralizing antibodies with glycan-dependent epitopes has revised the above view and showed that the human humoral immune system can actually pierce HIV-19s glycan shield [18,19,20,25,26,27,28].”
BackgroundSelf-citationKuchař, M., Kosztyu, P., Lišková, V., Černý, J., Petroková, H., Vróblová, E., Malý, M., Vaňková, L., Křupka, M., Kafkova, L. R., et al. (2021) · Virulence · doi:10.1080/21505594.2021.1920251 · Cited by 9
“containing N332 [11,12], high-mannose-type glycan, recognized by best-in-class V3-type bNAbs as PGT121, BG18, and 10–1074.”
Backgroundvan Haaren, M. M., McCoy, L. E., Torres, J. L., Lee, W., Cottrell, C. A., Copps, J., van der Woude, P., Yasmeen, A., de Taeye, S. W., de la Peña, A. T., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00094-21 · Cited by 8
Self-citationZhao, J., Song, E., Huang, Y., Yu, A., & Mechref, Y. S. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00587 · Cited by 8
Neralkar, M., Xu, B., Horiya, S., & Krauss, I. J. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00442 · Cited by 8
Malherbe, D. C., Sanders, R. W., van Gils, M. J., Park, B. S., Gomes, M. M., Schuitemaker, H., Barnett, S. W., & Haigwood, N. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075277 · Cited by 8
“Paradoxically, recent studies identified glycans as targets of the very potent PGT monoclonal antibodies (MAbs) [15,16].”
BackgroundSelf-citationAndrabi, R., Kumar, R., Bala, M., Nair, A., Biswas, A., Wig, N., Kumar, P., Pal, R., Sinha, S., & Luthra, K. (2012) · Virology Journal · doi:10.1186/1743-422x-9-196 · Cited by 8
“Nevertheless, the conserved epitopes on gp120 have been identified using antibodies from neutralizing sera [12-14] and bNAbs [9,10,15-17], which include the antibodies directed to the CD4 receptor binding site (CD4bs) and co-receptor binding site mainly the third variable region (V3) [10,18-22].”
BackgroundHu, G., Liu, J., Roux, K. H., & Taylor, K. A. (2017) · Journal of Virology · doi:10.1128/jvi.00134-17 · Cited by 8
“We used the atomic model of PGT122 as a mimic for 36D5 and fit it separately into the protruding density of 36D5 (Fig.”
BackgroundMethodInfluentialRingel, O., Müller, K., Koch, J., Brill, B., Wolf, T., Stephan, C., Vieillard, V., Debré, P., & Dietrich, U. (2017) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2017.0250 · Cited by 8
“BnAbs against HIV-1 need time to develop, as they require a mutual process of selection and adaptation to the coevolving HIV-1 quasispecies in the patient, finally resulting in bnAbs with peculiar features such as high affinity maturation, long HCDR3 loops, and so on.(62,63) However, bnAbs against HIV-1 are generated…”
BackgroundUltrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1
Xu, J., Zhou, T., McKee, K., Zhang, B., Liu, C., Nazzari, A. F., Pegu, A., Shen, C., Becker, J. E., Bender, M. F., et al. (2024) · Advanced Science · doi:10.1002/advs.202309268 · Cited by 7
Self-citationGermline-Targeting Strategies to Induce bNAbs against HIV-1
Atabey, T., Sanders, R. W., & Aldon, Y. (2025) · Current HIV Research · doi:10.2174/011570162x365229250527111140 · Cited by 7
Self-citationReceptor Binding Domain Based HIV Vaccines
Liu, H., Bi, W., Wang, Q., Lu, L., & Jiang, S. (2015) · BioMed Research International · doi:10.1155/2015/594109 · Cited by 7
Stable Isotope Labeling of Glycoproteins for NMR Study
Yamaguchi, Y., Yagi, H., & Kato, K. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/9781782623946-00194 · Cited by 8
Kafando, A., Martineau, C., Far, M. E., Fournier, É., Doualla‐Bell, F., Serhir, B., Kazienga, A., Sangaré, M. N., Sylla, M., Chamberland, A., et al. (2019) · Viruses · doi:10.3390/v11111012 · Cited by 7
“The V5 loop has been found to be necessary for viral structure integrity maintenance, negatively affected virus assembly and virus entry [62] and constituted neutralizing determinants recognized by broadly neutralizing monoclonal antibodies [63,64].”
BackgroundWu, N. R., Nicely, N. I., Lee, E. M., Reed, R. K., Watts, B. E., Cai, F., Walkowicz, W. E., Aussedat, B., Jones, J. A., Eaton, A., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008165 · Cited by 8
“PGT128, DH270, and PGT124 all have been shown to bind directly to Man8GlcNAc2 or Man9GlcNAc2 [20, 22, 27, 56], whereas PGT121 and PGT130 have been shown to bind processed glycans in addition to high mannose [57, 58].”
BackgroundConserved topology of virus glycoepitopes presents novel targets for repurposing HIV antibody 2G12
Miller, N. L., Subramanian, V., Clark, T., Raman, R., & Sasisekharan, R. (2022) · Scientific Reports · doi:10.1038/s41598-022-06157-z · Cited by 7
Clark, M., Li, H. J., Martin, M., Evangelous, T. D., Gobeil, S., Berry, M., Wagh, K., Giorgi, E. E., Hogarty, M. P., Zhao, C., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aee9864 · Cited by 6
Self-citationCAR T cell therapy beyond cancer: current status, challenges and future prospects
Upadhyay, S., Cho, S., Upmanyu, K., & Gabr, M. T. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02873-4 · Cited by 6
“34 First-generation CD4 ζ CARs con fi rmed the principle of targeting gp120 but rendered engineered T cells susceptible to infection through the introduced CD4 extracellular domain.”
Synthetic carbohydrate-based HIV-1 vaccines
Bastida, I., & Fernández‐Tejada, A. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.09.004 · Cited by 6
Li, Y., Bai, H., Sanders‐Buell, E., Dussupt, V., Townsley, S., Donofrio, G. C., Bose, M., O’Sullivan, A. M., Kibuuka, H. N., Maganga, L., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00797-21 · Cited by 6
Zong, G., Toonstra, C., Yang, Q., Zhang, R., & Wang, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212538 · Cited by 6
Reiche, S., Dwai, Y., Bußmann, B. M., Horn, S., Sieg, M., & Jassoy, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128684 · Cited by 6
Molecular Recognition of HIV Glycans by Antibodies
Kong, L., Stanfield, R. L., & Wilson, I. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8872-9_5 · Cited by 7
Self-citationAntibody Engineering and Therapeutics: December 8-12, 2013, Huntington Beach, CA
Almagro, J. C., Gilliland, G. L., Breden, F. J., Scott, J. K., Sok, D., Pauthner, M. G., Reichert, J. M., Helguera, G. F., Andrabi, R., Mabry, R., et al. (2014) · mAbs · doi:10.4161/mabs.28421 · Cited by 7
Toward a Carbohydrate-Based HIV-1 Vaccine
Kong, L., Julien, J., Calarese, D. A., Scanlan, C. N., Lee, H., Rudd, P. M., Wong, C., Dwek, R. A., Burton, D. R., & Wilson, I. A. (2012) · ACS symposium series · doi:10.1021/bk-2012-1102.ch007 · Cited by 8
Self-citationLiu, S., Bian, X., Zhao, F., Cao, M., Shang, Z., Li, B., & Zhang, X. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.136471 · Cited by 5
Haryadi, R., Chan, K. F., Lin, P. C., Tan, Y. L., Wan, C., Shahreel, W., Tay, S. J., Nguyen‐Khuong, T., Walsh, I., & Song, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-73722-z · Cited by 5
“Like PG9, PGT128 interacts with two high-mannose type N -glycans (Man9 and Man5), and the V3 loop region upon binding to an engineered gp120 outer domain 48 .”
BackgroundA sweet surprise for HIV broadly neutralizing antibodies
Langedijk, J. P. M., & Schuitemaker, H. (2012) · Nature Medicine · doi:10.1038/nm.2993 · Cited by 5
Adjuvants influence the maturation of VRC01-like antibodies during immunization
Knudsen, M. L., Agrawal, P., MacCamy, A. J., Parks, K. R., Gray, M. D., Takushi, B. N., Khechaduri, A., Salladay, K. R., Coler, R. N., LaBranche, C. C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105473 · Cited by 6
Antibody recognition of HIV and dengue glycoproteins
Krauss, I. J. (2016) · Glycobiology · doi:10.1093/glycob/cww031 · Cited by 5
“…in complex with PGT128 show that, in addition to the N332 glycan, this bnAb recognizes a glycan at N301 as well as backbone atoms of the 324GDIR327 peptide residues (a highly conserved motif; Garces et al. 2014) at the base of the V3 loop, and potentially other glycans (Pejchal et al. 2011).”
BackgroundExploitation of Glycobiology in Anti-Adhesion Approaches against Biothreat Agents
Utratna, M., Deegan, S., & Joshi, L. (2016) · Journal of Bioterrorism & Biodefense · doi:10.4172/2157-2526.1000150 · Cited by 5
“Thus, isolation of antibodies that bind the high mannose moieties of the gp120 was one of the biggest breakthroughs in the glycobiology field [50,51].”
SIV infection duration largely determines broadening of neutralizing antibody response in macaques
Wu, F., Ourmanov, I., Kirmaier, A., Leviyang, S., LaBranche, C. C., Huang, J., Whitted, S., Matsuda, K., Montefiori, D. C., & Hirsch, V. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139123 · Cited by 5
Glycan Arrays: Construction, Detection, and Analysis
Butler, D. L., Temme, J. S., & Gildersleeve, J. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00061-4 · Cited by 5
Lišková, V., Kosztyu, P., Kuchař, M., Černý, J., Bharadwaj, S., Petroková, H., Vróblová, E., Křupka, M., Malý, M., Zosinčuková, T., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1066361 · Cited by 5
“These reports further support the results that PGT128 and PGT126 promiscuously bind to the high mannose glycans in the context of the V3 loop peptide, in agreement with previously documented mutational analysis (45).”
ResultDoran, R. C., Morales, J. F., To, B., Morin, T. J., Theolis, R., Jr., O’Rourke, S. M., Yu, B., Mesa, K. A., & Berman, P. W. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.025 · Cited by 5
Xiang, S.-H. (2014) · Current HIV Research · doi:10.2174/1570162x113116660053 · Cited by 5
“These antibodies not only directly interact with HIV-1 glycans on the gp120, but can also penetrate the glycan shield to reach the short beta-strand segment of the gp120 V3-loop [51].”
BackgroundYu, Y., Fu, L., Jiang, X., Guan, S., Kuai, Z., Kong, W., Shi, Y., & Shan, Y. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.10.011 · Cited by 5
Lin, T.-Y., & Lai, J. R. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.013 · Cited by 5
Pauthner, M. G., & Hangartner, L. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_221 · Cited by 6
Synthesis of Mannosidase-Stable Man3 and Man4 Glycans Containing S-linked Manα1→2Man Termini
Neralkar, M., Tian, L., Redman, R. L., & Krauss, I. J. (2021) · Organic Letters · doi:10.1021/acs.orglett.1c00726 · Cited by 5
Immunogenicity Evaluation of N-Glycans Recognized by HIV Broadly Neutralizing Antibodies
Shivatare, S. S., Cheng, T.-J. R., Cheng, Y., Shivatare, V. S., Tsai, T.-I., Chuang, H.-Y., Wu, C., & Wong, C. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00375 · Cited by 5
Self-citationDing, S., Wang, H., Han, Z., & Hong, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1729274 · Cited by 4
“Early vaccine strategies aimed to recapitulate epitopes recognized by known bNAbs (128).”
An HIV-1 Envelope Glycoprotein Trimer with an Embedded IL-21 Domain Activates Human B Cells
Isik, G., Chung, N. P. Y., van Montfort, T., Menis, S., Matthews, K., Schief, W. R., Moore, J. P., & Sanders, R. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067309 · Cited by 4
Self-citationLamers, S. L., Fogel, G. B., Liu, E. S., Salemi, M., & McGrath, M. S. (2016) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0373 · Cited by 4
Determinants of HIV-1 CD4-Independent Brain Adaptation
Shakirzyanova, M., Kong, X., & Cheng‐Mayer, C. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001478 · Cited by 4
Can we use structural knowledge to design a protective vaccine against HIV‐1?
Björkman, P. J. (2019) · HLA · doi:10.1111/tan.13759 · Cited by 4
“V3/N332 glycan-targeting bNAbs can adopt different Env-binding orientations,(49,64) but the 10-1074 orientation in our 10-1074-IOMA-Env structure resembled orientations of PGT121-124-family bNAbs.(49,52,67) In addition to interactions with the high mannose N332gp120 glycan, 10-1074 is surrounded by complex-type glycan…”
BackgroundGlyconanoparticles as versatile platforms for vaccine development: A minireview
Polito, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820954-7.00011-6 · Cited by 5
Stanfield, R. L., & Wilson, I. A. (2015) · ASM Press eBooks · doi:10.1128/9781555817411.ch3 · Cited by 4
Self-citationTargeting Glycans of HIV Envelope Glycoproteins for Vaccine Design
Behrens, A., Seabright, G. E., & Crispin, M. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/9781782623823-00300 · Cited by 5
Self-citationvan Montfort, T., Thomas, A. A. M., Krawczyk, P. M., Berkhout, B., Sanders, R. W., & Paxton, W. A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402344 · Cited by 4
“32 PGT128 V3 N295/N301/N332 (51, 53, 54) NN 1 NN↑ PGT151 gp41–gp120 interface, quaternary N611/N637 (55, 56) 0.”
Self-citationImproved outlook on HIV-1 prevention and vaccine development
Vasan, S., & Michael, N. L. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.688020 · Cited by 4
“Vaccine immunogens must, therefore, target the few regions that are relatively conserved, yet exposed, or elicit responses capable of penetrating the glycan shield [52].”
BackgroundArchary, D., Rong, R., Gordon, M. L., Boliar, S., Madiga, M., Gray, E. S., Dugast, A., Hermanus, T., Goulder, P., Coovadia, H. M., et al. (2012) · Virology · doi:10.1016/j.virol.2012.08.033 · Cited by 4
González, S. A., & Affranchino, J. L. (2016) · Archives of Virology · doi:10.1007/s00705-016-2843-6 · Cited by 4
“neutralizing antibodies isolated from HIV-1-infected patients target conserved glycans of HIV-1 gp120 [27].”
BackgroundKusumoto, M., Ueno‐Noto, K., & Takano, K. (2019) · Journal of Computational Chemistry · doi:10.1002/jcc.26073 · Cited by 4
GLYCO-BUILD: an enzymatic pipeline for the synthesis of peptides carrying eukaryotic N-glycans
Rossi, L., Alexander, J. A. N., Ramίrez, A. S., & Locher, K. P. (2025) · Nature Communications · doi:10.1038/s41467-025-67055-2 · Cited by 3
“Given that PGT128 and other Fabs have been shown to interact with only two N -glycans (at N301 and N332, but not N295) 12,14,61,62 , we generated a second peptide, termed V3-mini-opti-mized, which contained two acceptor sequons for glycosylation at N301 and N332 and engineered for ef fi cient processing by Tb STT3A (Fi…”
Decoding the glycan shield: Immune recognition and response to the HIV-1 envelope trimer
Nawaz, F. Z., Adams, T. M., Demirturk, M. E., & Avci, F. Y. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111350 · Cited by 3
“Several bnAbs, including PG9, PGT128, and members of the PGT121–123/PGT13 3–134/10–1074, PGT125–128/PGT130–131, and PGT135–137 families, recognize and exploit glycan-dependent epitopes on the HIV Env glycoprotein (37, 48, 90, 99).”
Burnie, J., Ouano, C., Costa, V., Castrosín, I., Hammond, C., Matthews, H. R., Tigges, J., & Corbett, K. S. (2026) · Virology Journal · doi:10.1186/s12985-026-03169-3 · Cited by 3
“These features increase overall experimental acquisition length, reducing the capacity for high throughput applications.”
Mapping antibody footprints using binding profiles
Azulay, A., Cohen-Lavi, L., Friedman, L. M., McGargill, M. A., & Hertz, T. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100566 · Cited by 3
Assessing immunogenicity barriers of the HIV-1 envelope trimer
Maliqi, L., Friedrich, N., Glögl, M., Schmutz, S., Schmidt, D. G., Rusert, P., Schanz, M., Zaheri, M., Pasin, C., Niklaus, C. R., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00746-3 · Cited by 3
“Many bnAbs gain access to dif fi cult-to-reach epitopes through long CDRH3 regions 53,57,58 .”
BackgroundSelf-citationDemirkıran, N., Aydın, B., Pehlivan, M., Yüce, Z., & Sercan, H. O. (2024) · Medical Oncology · doi:10.1007/s12032-024-02336-2 · Cited by 3
The Influence of HIV Envelope Glycosylation on Adaptive Immune Response
Hioe, C. E., Kumar, R., & Hu, S. L. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8872-9_3 · Cited by 4
Glycosylation in HIV-1 Envelope Glycoprotein and its Biological Implications
Ho, Y. S., & Saksena, N. K. (2013) · Future Virology · doi:10.2217/fvl.13.64 · Cited by 3
Metadata
- Authors
- Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P.-S., Wang, S.-K., Stanfield, R. L., Julien, J.-P., Ramos, A., Crispin, M., Depetris, R., Katpally, U., Marozsan, A., Cupo, A., Maloveste, S., Liu, Y., McBride, R., Ito, Y., Sanders, R. W., Ogohara, C., Paulson, J. C., Feizi, T., Scanlan, C. N., Wong, C.-H., Moore, J. P., Olson, W. C., Ward, A. B., Poignard, P., Schief, W. R., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- University of Washington (US)
- University of Oxford (GB)
- Cornell University (US)
- Progenics Pharmaceuticals (United States) (US)
- National Institutes of Health (US)
- Imperial College London (GB)
- Japan Science and Technology Agency (JP)
- Corresponding author
- Pejchal, Robert
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Burton, Dennis R.
- Wilson, Ian A.
- ORCID
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Wang, Sheng-Kai
- Stanfield, Robyn L.
- Julien, Jean-Philippe
- Crispin, Max
- Depetris, Rafael
- Cupo, Albert
- Liu, Yan
- McBride, Ryan
- Ito, Yukishige
- Sanders, Rogier W.
- Paulson, James C.
- Feizi, Ten
- Wong, Chi-Huey
- Moore, John P.
- Olson, William C.
- Ward, Andrew B.
- Poignard, Pascal
- Schief, William R.
- Burton, Dennis R.
- Wilson, Ian A.
- Venue
- Science
- Published
- 2011-11-25
- Volume
- 334
- Issue
- 6059
- Pages
- 1097-1103
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3280215
- OpenAlex
- W2128579789
- Cited by
- 694
- References
- 75
- Citations by year
- 2026: 23 · 2025: 12 · 2024: 18 · 2023: 19 · 2022: 25 · 2021: 35 · 2020: 34 · 2019: 37 · 2018: 54 · 2017: 54 · 2016: 62 · 2015: 70 · 2014: 69 · 2013: 105 · 2012: 72
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Canadian Institutes of Health Research (HFE-224662)
- Engineering and Physical Sciences Research Council (EP/G037604/1, GR/S79268/02)
- National Cancer Institute (Y1-CO-1020, U01CA128416)
- National Institute of General Medical Sciences (Y1-GM-1104)
- National Institute of Allergy and Infectious Diseases (AI-33292, F32AI074372, AI74372, R37AI033292, R56AI084817, P01AI082362, AI082362, R01AI033292, R01AI084817, AI84817)
- National Center for Research Resources (P41RR001209, RR017573, P41RR017573)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- HIV-1, broadly neutralizing antibodies, gp120, glycan shield, V3 loop, antibody penetration
- MeSH terms
- Antibody Specificity, Epitopes, Binding Sites, Antibody, Carbohydrate Conformation, Cell Line, Disaccharides, Glycosylation, Humans, Hydrogen Bonding, Immunoglobulin Fab Fragments, Mannose, Mannosides, Models, Molecular, Mutation, Oligosaccharides, Polysaccharides, Protein Conformation, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, Protein Structure, Tertiary, Crystallography, X-Ray, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.